Renalytix announces opening the commercial availability of kidneyintelX.dkd testing in Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and United Arab Emirates through a distribution agreement with Vector Pharma. Following the recent announcement of FDA marketing authorization for kidneyintelX.dkd, Renalytix will take advantage of select opportunities to expand testing services outside the US market with qualified distribution partners. In the six markets of the Gulf Cooperation Council, the International Diabetes Federation has reported high prevalence rates of diabetes, with more than 20% of the population being diabetic and more than 15% being pre-diabetic in most GCC countries. These are among the highest reported incidence rates for diabetes globally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNLX:
- Renalytix Announces Middle East Distribution Agreement with Vector Pharma
- Renalytix management to meet virtually with BTIG
- Renalytix announces clinical data on KidneyIntelX in vitro prognostic use
- Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
- Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors